Summary & Overview
HCPCS G2215: Take-Home Nasal Naloxone 2-Pack
Headline: HCPCS Level II code G2215: Take-home nasal naloxone pack for opioid treatment programs
Lead: HCPCS Level II code G2215 identifies the distribution of a take-home nasal naloxone 2-pack (4 mg per 0.1 ml) by a Medicare-enrolled opioid treatment program, billed in addition to the primary procedure. This code supports overdose prevention efforts by enabling programs to provide opioid antagonists directly to patients on discharge or during treatment visits.
What it represents and national importance: The code covers the physical supply of naloxone intended for patient use outside the clinical setting. Nationally, such supplies are a critical component of harm reduction strategies and emergency preparedness for individuals with opioid use disorder. Billing for the supply separate from clinical encounters clarifies reimbursement pathways for programs that incorporate take-home naloxone distribution into care workflows.
Key payers covered: Analysis addresses major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication outlines billing context for G2215, payer coverage considerations, typical sites of service and clinical context for take-home naloxone distribution, and common modifiers used in practice. It highlights where input data is incomplete and directs readers to seek payer-specific policies for coverage and billing guidance.
Billing Code Overview
HCPCS Level II code G2215 denotes the take-home supply of nasal naloxone provided by a Medicare-enrolled opioid treatment program. The code specifically describes a 2-pack of 4 mg per 0.1 ml nasal spray supplied to a patient and is reported separately in addition to the code for the primary procedure.
Service Type: Medication supply / take-home naloxone provision
Typical Site of Service: Opioid Treatment Program (OTP) or outpatient clinic affiliated with an OTP
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A patient enrolled in a Medicare-certified opioid treatment program (OTP) presents for routine follow-up after stabilization on methadone therapy. The patient has reported periods of high overdose risk related to recent illicit opioid exposure in their social network. The OTP clinician reviews overdose prevention education, demonstrates use of a naloxone nasal spray device, documents counseling, and provides a take-home supply of naloxone consisting of a 2-pack of 4 mg per 0.1 mL nasal spray. The supply is dispensed onsite by the OTP pharmacy or program staff, and the provision is billed separately in addition to the primary OTP service visit using the HCPCS Level II code G2215.
Workflow steps:
-
Patient check-in and brief screening for current opioid use and overdose risk.
-
Clinician-led overdose education and naloxone administration demonstration with return demonstration by the patient when feasible.
-
Documentation of education, device lot number/expiration, and quantity dispensed in the medical record.
-
Dispensing the
G2215naloxone 2-pack from OTP inventory, provision of written instructions and emergency contact information. -
Billing:
G2215is listed separately in addition to the primary OTP procedure or service. Appropriate modifiers may be appended per payer and circumstance.